Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis.

Kamran M, Long ZJ, Xu D, Lv SS, Liu B, Wang CL, Xu J, Lam EW, Liu Q.

Oncogenesis. 2017 Feb 20;6(2):e298. doi: 10.1038/oncsis.2016.80.

2.

Understanding the role of PIN1 in hepatocellular carcinoma.

Cheng CW, Leong KW, Tse E.

World J Gastroenterol. 2016 Dec 7;22(45):9921-9932. doi: 10.3748/wjg.v22.i45.9921. Review.

3.

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells.

Gonçalves-Ribeiro S, Díaz-Maroto NG, Berdiel-Acer M, Soriano A, Guardiola J, Martínez-Villacampa M, Salazar R, Capellà G, Villanueva A, Martínez-Balibrea E, Molleví DG.

Oncotarget. 2016 Sep 13;7(37):59766-59780. doi: 10.18632/oncotarget.11121.

4.

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.

Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX.

Oncotarget. 2016 Aug 30;7(35):56864-56875. doi: 10.18632/oncotarget.10870.

5.

αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor.

Lu H, Wang T, Li J, Fedele C, Liu Q, Zhang J, Jiang Z, Jain D, Iozzo RV, Violette SM, Weinreb PH, Davis RJ, Gioeli D, FitzGerald TJ, Altieri DC, Languino LR.

Cancer Res. 2016 Sep 1;76(17):5163-74. doi: 10.1158/0008-5472.CAN-16-0543.

PMID:
27450452
6.

TAT-IL-24-KDEL-induced apoptosis is inhibited by survivin but restored by the small molecular survivin inhibitor, YM155, in cancer cells.

Zhang J, Xu R, Tao X, Dong Y, Lv X, Sun A, Wei D.

Oncotarget. 2016 Jun 14;7(24):37030-37042. doi: 10.18632/oncotarget.9458.

7.

A novel microtubule inhibitor, MT3-037, causes cancer cell apoptosis by inducing mitotic arrest and interfering with microtubule dynamics.

Chang LC, Yu YL, Hsieh MT, Wang SH, Chou RH, Huang WC, Lin HY, Hung HY, Huang LJ, Kuo SC.

Am J Cancer Res. 2016 Mar 15;6(4):747-63.

8.

Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/Stat3 signaling.

Rodriguez JA, Huerta-Yepez S, Law IK, Baay-Guzman GJ, Tirado-Rodriguez B, Hoffman JM, Iliopoulos D, Hommes DW, Verspaget HW, Chang L, Pothoulakis C, Baritaki S.

Cell Mol Gastroenterol Hepatol. 2015 Nov 1;1(6):610-630.

9.

Novel 3-Substituted 7-Phenylpyrrolo[3,2-f]quinolin-9(6H)-ones as Single Entities with Multitarget Antiproliferative Activity.

Carta D, Bortolozzi R, Hamel E, Basso G, Moro S, Viola G, Ferlin MG.

J Med Chem. 2015 Oct 22;58(20):7991-8010. doi: 10.1021/acs.jmedchem.5b00805.

10.

Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer.

Debeb BG, Smith DL, Li L, Larson R, Xu W, Woodward WA.

PLoS One. 2015 Mar 12;10(3):e0120719. doi: 10.1371/journal.pone.0120719.

11.

Recent Advances on Small-Molecule Survivin Inhibitors.

Xiao M, Li W.

Curr Med Chem. 2015 Jan 13. [Epub ahead of print]

12.

Survivin - The inconvenient IAP.

Altieri DC.

Semin Cell Dev Biol. 2015 Mar;39:91-6. doi: 10.1016/j.semcdb.2014.12.007. Review.

13.

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer.

Baker AT, Zlobin A, Osipo C.

Front Oncol. 2014 Dec 12;4:360. doi: 10.3389/fonc.2014.00360. Review.

14.

CDK1 plays an important role in the maintenance of pluripotency and genomic stability in human pluripotent stem cells.

Neganova I, Tilgner K, Buskin A, Paraskevopoulou I, Atkinson SP, Peberdy D, Passos JF, Lako M.

Cell Death Dis. 2014 Nov 6;5:e1508. doi: 10.1038/cddis.2014.464.

15.

Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair.

Qin Q, Cheng H, Lu J, Zhan L, Zheng J, Cai J, Yang X, Xu L, Zhu H, Zhang C, Liu J, Ma J, Zhang X, Dai S, Sun X.

J Hematol Oncol. 2014 Aug 20;7:62. doi: 10.1186/s13045-014-0062-8.

16.

Nanoformulated cell-penetrating survivin mutant and its dual actions.

Sriramoju B, Kanwar RK, Kanwar JR.

Int J Nanomedicine. 2014 Jul 10;9:3279-98. doi: 10.2147/IJN.S60169.

17.

Small-molecule inhibitors of the Myc oncoprotein.

Fletcher S, Prochownik EV.

Biochim Biophys Acta. 2015 May;1849(5):525-43. doi: 10.1016/j.bbagrm.2014.03.005. Review.

18.

Survivin as a preferential target for cancer therapy.

Mobahat M, Narendran A, Riabowol K.

Int J Mol Sci. 2014 Feb 13;15(2):2494-516. doi: 10.3390/ijms15022494. Review.

19.

Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.

Wang J, Lu Z, Yeung BZ, Wientjes MG, Cole DJ, Au JL.

J Control Release. 2014 Mar 28;178:79-85. doi: 10.1016/j.jconrel.2014.01.012.

20.

Colorectal cancer stem cells and cell death.

Catalano V, Gaggianesi M, Spina V, Iovino F, Dieli F, Stassi G, Todaro M.

Cancers (Basel). 2011 Apr 11;3(2):1929-46. doi: 10.3390/cancers3021929.

Supplemental Content

Support Center